| abstract |
The present invention relates to bridged heterocyclyl-substituted pyrimidines and their preparation methods and pharmaceutical uses. In particular, the present invention relates to a compound represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the same, and its use as a JAK1 and TYK2 kinase inhibitor, and its use in the treatment of a disease associated with JAK1 and TYK2 kinase activity, such as inflammation, autoimmune diseases, cancer, etc. The definitions of each substituent in the general formula (I) are the same as those in the specification. |